Growth Hormone Receptor Antagonist Applications in Water Quality Monitoring, Agriculture, and Biomedical Diagnostics

Publication ID: 24-11857602_0007_PTD

Published: October 28, 2025

Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Growth Hormone Receptor Antagonist Applications in Water Quality Monitoring, Agriculture, and Biomedical Diagnostics,” Published Technical Disclosure No. 24-11857602_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857602_0007_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,602.

Summary of the Inventive Concept

The inventive concept leverages the core technology of growth hormone receptor antagonists to develop novel applications in water quality monitoring, agriculture, and biomedical diagnostics, providing innovative solutions for various industries.

Background and Problem Solved

The original patent disclosed a composition for treating cancer and other diseases using modified human growth hormone receptor antagonists. However, the patent's scope was limited to pharmaceutical applications. This inventive concept addresses the need for applying the core technology to entirely different industries, such as environmental monitoring, agriculture, and biomedical diagnostics, where growth hormone receptor antagonists can provide unique benefits.

Detailed Description of the Inventive Concept

The inventive concept comprises four main applications: (1) a system for monitoring water quality by detecting growth hormone receptor expression in aquatic organisms, enabling early warnings for waterborne diseases; (2) a method for predicting crop yield by applying modified human growth hormone receptor antagonists to crops, enhancing plant growth and development; (3) a device for diagnosing neurodegenerative disorders by detecting growth hormone receptor expression in neural tissue, facilitating early disease detection; and (4) a system for optimizing livestock feed by detecting growth hormone receptor expression in livestock, ensuring optimal feed composition.

Novelty and Inventive Step

The inventive concept's novelty lies in the unexpected application of growth hormone receptor antagonists to non-pharmaceutical fields, where their unique properties provide innovative solutions. The inventive step resides in the recognition of the potential for growth hormone receptor antagonists to address specific problems in water quality monitoring, agriculture, and biomedical diagnostics.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different types of sensors or probes for detecting growth hormone receptor expression, or the development of novel formulations for the modified human growth hormone receptor antagonists. Variations of the inventive concept may also include the application of growth hormone receptor antagonists to other industries, such as veterinary medicine or biotechnology.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the environmental monitoring, agriculture, and biomedical diagnostics industries, with potential markets including water treatment facilities, agricultural companies, and biomedical research institutions.

CPC Classifications

Section	Class	Group
A	A61	A61K38/27
A	A61	A61K45/06
A	A61	A61K47/10
A	A61	A61P35/00
A	A61	A61K2039/505

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology and pharmaceutical research, focusing on protein engineering, receptor antagonists, and therapeutic compositions with expertise in molecular biology, protein modification, and receptor interaction analysis

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or biochemistry, proficient in protein engineering techniques, receptor interaction analysis, and familiar with growth hormone receptor antagonist technologies

Obviousness Rationale

A PHOSITA would recognize the inherent versatility of growth hormone receptor antagonists based on the source patent's detailed molecular characterization, understanding that these molecules could be adapted for diagnostic and monitoring applications beyond cancer treatment. The structural modifications and receptor interaction principles disclosed in the source patent provide a clear framework for exploring alternative technological applications. The PTD's proposed variations represent predictable extensions of known protein engineering principles applied to novel detection and monitoring contexts.

Obvious Combinations & Variations

Source Patent Element

Modified human growth hormone receptor antagonist with specific amino acid substitutions (G120K, H18D, H21N)

PTD Variation

Application of modified antagonist for water quality monitoring and detecting receptor expression in aquatic organisms

Obviousness Reasoning

A PHOSITA would recognize that receptor detection methods are a standard technique in molecular biology, and the structural characteristics of the antagonist make it suitable for sensing applications through predictable protein engineering approaches

Source Patent Element

Polyethylene glycol conjugation method for molecular modification

PTD Variation

Adapting PEG conjugation techniques for creating sensors and diagnostic probes in agricultural and neurological contexts

Obviousness Reasoning

PEG modification is a well-established technique for enhancing protein stability and detection capabilities, making its application to sensing technologies a predictable design choice

Source Patent Element

Cancer-related growth hormone receptor expression analysis

PTD Variation

Extending receptor expression analysis to crop yield prediction and livestock feed optimization

Obviousness Reasoning

Detecting receptor expression patterns is a fundamental molecular biology technique that can be readily translated across biological systems using standard molecular analysis methods

Source Patent Element

Combination therapy approach targeting specific receptor interactions

PTD Variation

Developing multi-purpose detection systems leveraging receptor interaction principles

Obviousness Reasoning

A PHOSITA would understand that receptor interaction principles are transferable across different biological contexts, making interdisciplinary application a logical extension of the original research

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the published technical disclosure would have been obvious to a person having ordinary skill in the art at the time of invention, as the proposed applications represent predictable extensions of the molecular principles and protein engineering techniques disclosed in US Patent 11857602, with a reasonable expectation of success based on established biotechnological methodologies.

Original Patent Information

Patent Number	US 11,857,602
Title	Growth hormone antagonist and anti-cancer composition combination therapy